Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Appointed director
|
|
Sonoma Pharmaceuticals, Inc. (SNOA)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/15/2021 |
GN
| BREAKING ALERT: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Sonoma Pharmaceuticals, Inc. Investors with Losses to Inquire About Securities Class Action Investigation – SNOA |
| 02/02/2021 |
GN
| Sonoma Pharmaceuticals, Inc.: Company Investigated by the Portnoy Law Firm |
| 12/19/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA |
| 12/07/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sonoma Pharmaceuticals, Inc. - SNOA |
| 12/02/2020 |
GN
| ROSEN, RESPECTED INVESTOR COUNSEL, Continues to Investigate Securities Claims Against Sonoma Pharmaceuticals, Inc. – SNOA |
| 11/30/2020 |
GN
| SONOMA PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sonoma Pharmaceuticals, Inc. on Behalf of Sonoma Stockholders and Encourages Investors to Contact the Firm |
| 11/30/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Sonoma Pharmaceuticals, Inc. – SNOA |
| 11/25/2020 |
GN
| Sonoma Pharmaceuticals, Inc. Investors: Company Investigated by the Portnoy Law Firm |
| 02/27/2020 |
GN
| Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group |
| 02/14/2020 |
GN
| Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results |
| 11/29/2019 |
GN
| Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock |
| 11/26/2019 |
GN
| Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock |
| 11/25/2019 |
GN
| Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock |
| 11/14/2019 |
GN
| Sonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results |
| 10/01/2019 |
GN
| Sonoma Pharmaceuticals Announces Management Changes |
| 08/13/2019 |
GN
| Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results |
| 07/08/2019 |
GN
| Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2019 Financial Results |
| 06/19/2019 |
GN
| Sonoma Pharmaceuticals Announces 1-for-9 Reverse Split of Outstanding Common Stock |
| 12/14/2018 |
GN
| Sonoma Pharmaceuticals Announces Management Changes |
| 11/17/2018 |
GN
| Sonoma Pharmaceuticals Announces Pricing of Public Offering of Units |
| 11/01/2018 |
GN
| Sonoma Pharmaceuticals Announces Second Quarter FY 2019 Financial Results and Conference Call |
| 10/17/2018 |
GN
| Sonoma Pharmaceuticals Launches New Ceramax™ Skin Barrier Lotion with Skin-Enriching Lipogrid Technology™ |
| 09/26/2018 |
GN
| Sonoma Pharmaceuticals Announces Licensing of Antimicrobial Hypochlorous Acid Solution for Management of Blepharitis in the Spanish/Portuguese Markets to Brill Pharma, S.L. |
| 09/19/2018 |
GN
| Sonoma Pharmaceuticals Appoints Phillipe Weigerstorfer to Board of Directors |
| 08/28/2018 |
GN
| Sonoma Pharmaceuticals Announces Results from Study of Sonoma's Performance-Stabilized HOCl™ (Hypochlorous Acid) in Management of Acne Vulgaris |
| 07/25/2018 |
GN
| Sonoma Pharmaceuticals Announces First Quarter FY 2019 Financial Results and Conference Call |
| 06/13/2018 |
GN
| Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results |
| 06/05/2018 |
GN
| U.SK, dermatology arm of Brazilian NC Group, and Sonoma Pharmaceuticals Enter into License Agreement for Exclusive Rights to Sonoma's Dermatology Products in Brazil |
| 05/31/2018 |
GN
| Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call |
| 05/08/2018 |
GN
| Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer |
| 04/17/2018 |
GN
| Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products |
| 04/05/2018 |
GN
| Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel |
| 03/27/2018 |
GN
| Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution |
| 03/09/2018 |
GN
| Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018 |
|
|
|